Antibodies to Mitotic Spindle Apparatus: Clinical Significance of NuMA and HsEg5 Autoantibodies
- 311 Downloads
The clinical associations of NuMA and HsEg5 antibodies, the main anti-mitotic spindle apparatus autoantibodies, remain unclear due to their extremely low prevalence.
Patients and Methods
We have analysed the clinical data of 40 anti-NuMA- (0.87‰) and 7 anti-HsEg5- (0.15‰) positive patients detected during routine immunofluorescence examination of 45,804 sera. NuMA reactivity was further confirmed by immunoblotting.
Antibodies to HsEg5 did not associate with any specific pathology. NuMA positivity associated with a diagnosis of connective tissue disease (CTD) in 18 patients (45%), primary Sjögren or sicca syndrome and undifferentiated connective tissue disease being the most represented. Seven patients (17.5%) were diagnosed with different organ-specific autoimmune diseases, whereas in the other 15 patients (37.5%), no autoimmune pathology could be documented.
Therefore, although both anti-mitotic spindle apparatus antibodies are not associated to a defined autoimmune pathology, the presence of NuMA antibodies, mainly at high titers, may be an indication for a more extensive screening of CTD.
KeywordsMitotic spindle apparatus autoantibodies NuMA protein HsEg5 protein connective tissue diseases
This work was supported in part by the Asociación Lúpicos de Asturias (Association of lupus patients of Asturias, Spain).
- 14.Claus R, Hickstein H, Külz T, Lenschow U, Meiske D, Kotitscke A, et al. Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen. Rheumatol Int. 2006;26:886–95.PubMedCrossRefGoogle Scholar
- 18.Lonzetti SL, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44:735–6.PubMedCrossRefGoogle Scholar